About Cytochrome b-c1 complex subunit Rieske, mitochondrial
Cytochrome b-c1 complex subunit Rieske, mitochondrial (UQCRFS1) is a protein
from Homo sapiens identified by UniProt accession
P47985, 274 residues long.
MolForge cross-references it against 0 known binders and
84 disease associations.
Target properties
| Protein name | Cytochrome b-c1 complex subunit Rieske, mitochondrial |
|---|
| UniProt accession | P47985 |
|---|
| Gene | UQCRFS1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 274 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (84)
Diseases linked to this target (Open Targets).
- mitochondrial complex 3 deficiency, nuclear type 10 · score 0.70
- neurodegenerative disease · score 0.48
- cardiomyopathy · score 0.46
- lactic acidosis · score 0.46
- propionic acidemia · score 0.46
- Isolated CoQ-cytochrome C reductase deficiency · score 0.37
- reticulocyte count · score 0.16
- PHF-tau measurement · score 0.11
- smoking status measurement · score 0.10
- depressive disorder · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P47985-F1 | alphafold | PREDICTED | 80.76 | — |
Amino-acid sequence (274 residues)
MLSVASRSGP FAPVLSATSR GVAGALRPLV QATVPATPEQ PVLDLKRPFL SRESLSGQAV RRPLVASVGL NVPASVCYSH TDIKVPDFSE YRRLEVLDST KSSRESSEAR KGFSYLVTGV TTVGVAYAAK NAVTQFVSSM SASADVLALA KIEIKLSDIP EGKNMAFKWR GKPLFVRHRT QKEIEQEAAV ELSQLRDPQH DLDRVKKPEW VILIGVCTHL GCVPIANAGD FGGYYCPCHG SHYDASGRIR LGPAPLNLEV PTYEFTSDDM VIVG
Explore Cytochrome b-c1 complex subunit Rieske, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets